NASDAQ · Biotechnology · USD

SAB Biotherapeutics, Inc. (SABS) Stock Analysis

SAB Biotherapeutics, Inc. (SABS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SABS

$3.72

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SABS with… →

SABS Key Statistics

As of Sep 4, 2026

Trading

Open: $3.72
Previous Close: $3.72
Day's Range: 3.70–3.75
52-Week Range: 1.85–5.15
Volume: 110.60K
Beta: 0.54

Valuation

Market Cap: $338.47M
P/E Ratio: 15.50
EPS (ttm): 0.24

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): $13.27M
Profit margin: 0.00%
Shares Outstanding: 90.99M
1-Year Return: +64.60%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 666.84K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SABS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−23.05%−92.45%+16.61%−44.85%−1.42%−0.53%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−0.53%
2025	−1.42%
2024	−44.85%
2023	+16.61%
2022	−92.45%
2021 (partial year)	−23.05%

As of September 4, 2026.

SABS Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	$13.27M	—
2024	$0.00	−$34.11M	—
2023	$0.00	−$42.19M	—
2022	$0.00	−$18.74M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$48.95M	$13.27M	—
2024	$0.00	—	−$42.91M	−$34.11M	—
2023	$0.00	—	−$38.08M	−$42.19M	—
2022	$0.00	—	−$28.92M	−$18.74M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SABS Valuation vs Biotechnology Median

Median of 656 stocks

Metric	SABS	Biotechnology median	vs median
P/E	15.50	12.57	23% above
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

SAB Biotherapeutics, Inc. (SABS) is capitalised at $338.47M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 86 employees.

Over the past 52 weeks the price has ranged from $1.85 to $5.15. SABS last closed at $3.72 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 101.08% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with net income of $13.27M. The reported profit margin is 0%. Trailing earnings per share are 0.24.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 15.5. That is 23.31% above the Biotechnology median of 12.57. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.54. Daily returns over the trailing 5 years annualize to a volatility of 112.61%. The trailing one-year price return is +64.60%. Measured over 5 years, that is −48.22% a year compounded.

Growth & Income

The record shows no dividend for SABS.

So far in 2026 the price is −0.53%. The strongest complete calendar year on file is 2023 at +16.61%; the weakest is 2022 at −92.45%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

SAB Biotherapeutics, Inc. (SABS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
SAB Biotherapeutics, Inc.	SABS	$338.47M	15.5
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. SAB Biotherapeutics, Inc. trades at a P/E of 15.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Visit website →